Novo Nordisk Stock Dives On Forecast for 2026 Sales Drop

Dow Jones02:17

Novo Nordisk's U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its popular diabetes and weight-loss drugs.

The Danish company said it expects global full-year 2026 sales to drop between 5% and 13% from 2025 levels, excluding currency fluctuations. In comparison, sales rose 10% for full-year 2025.

The company said that U.S. sales should decline because of lower prices for drugs including Ozempic and Wegovy, citing its recent agreement with the Trump administration to cut prices. The active ingredient of both drugs also will lose patent exclusivity in certain countries outside the U.S., which could clear the way for low-cost generic competition.

The diminished outlook is the latest piece of bad news for the once high-flying company, which helped pioneer the weight-loss drug market.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608801649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 02:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608801649","market":"us","top_or_hot":-1,"title":"Novo Nordisk Stock Dives On Forecast for 2026 Sales Drop","media":"Dow Jones","content":"<p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its popular diabetes and weight-loss drugs.</p><p>The Danish company said it expects global full-year 2026 sales to drop between 5% and 13% from 2025 levels, excluding currency fluctuations. In comparison, sales rose 10% for full-year 2025.</p><p>The company said that U.S. sales should decline because of lower prices for drugs including Ozempic and Wegovy, citing its recent agreement with the Trump administration to cut prices. The active ingredient of both drugs also will lose patent exclusivity in certain countries outside the U.S., which could clear the way for low-cost generic competition.</p><p>The diminished outlook is the latest piece of bad news for the once high-flying company, which helped pioneer the weight-loss drug market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Stock Dives On Forecast for 2026 Sales Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Stock Dives On Forecast for 2026 Sales Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-04 02:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its popular diabetes and weight-loss drugs.</p><p>The Danish company said it expects global full-year 2026 sales to drop between 5% and 13% from 2025 levels, excluding currency fluctuations. In comparison, sales rose 10% for full-year 2025.</p><p>The company said that U.S. sales should decline because of lower prices for drugs including Ozempic and Wegovy, citing its recent agreement with the Trump administration to cut prices. The active ingredient of both drugs also will lose patent exclusivity in certain countries outside the U.S., which could clear the way for low-cost generic competition.</p><p>The diminished outlook is the latest piece of bad news for the once high-flying company, which helped pioneer the weight-loss drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608801649","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608801649","pubTimestamp":1770142620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk's U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its popular diabetes and weight-loss drugs.The Danish company said it expects global full-year 2026 sales to drop between 5% and 13% from 2025 levels, excluding currency fluctuations. In comparison, sales rose 10% for full-year 2025.The company said that U.S. sales should decline because of lower prices for drugs including Ozempic and Wegovy, citing its recent agreement with the Trump administration to cut prices. The active ingredient of both drugs also will lose patent exclusivity in certain countries outside the U.S., which could clear the way for low-cost generic competition.The diminished outlook is the latest piece of bad news for the once high-flying company, which helped pioneer the weight-loss drug market.This item is part of a Wall Street Journal live coverage event. The full stream","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVOX":"2倍做多NVO ETF-Defiance"},"translate_title":"诺和诺德股价因2026年销售额下降预测而跳水——《华尔街日报》","themeId":"af4d35cc6f66a4e728905d964bf712fc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":2,"NVO":1.98,"NVOX":2},"content_text":"Novo Nordisk's U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its popular diabetes and weight-loss drugs.The Danish company said it expects global full-year 2026 sales to drop between 5% and 13% from 2025 levels, excluding currency fluctuations. In comparison, sales rose 10% for full-year 2025.The company said that U.S. sales should decline because of lower prices for drugs including Ozempic and Wegovy, citing its recent agreement with the Trump administration to cut prices. The active ingredient of both drugs also will lose patent exclusivity in certain countries outside the U.S., which could clear the way for low-cost generic competition.The diminished outlook is the latest piece of bad news for the once high-flying company, which helped pioneer the weight-loss drug market.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608801649","isCrawlerRequest":true}